349 related articles for article (PubMed ID: 27071973)
1. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
Sun S; Li J; Li X; Lan B; Zhou S; Meng Y; Cheng L
Acta Biomater; 2016 Jun; 37():143-54. PubMed ID: 27071973
[TBL] [Abstract][Full Text] [Related]
2. Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-ε-caprolactone matrix.
Meng Y; Sun S; Li J; Nan K; Lan B; Jin Y; Chen H; Cheng L
Acta Biomater; 2014 Jan; 10(1):126-33. PubMed ID: 24076072
[TBL] [Abstract][Full Text] [Related]
3. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous.
Li J; Lan B; Li X; Sun S; Lu P; Cheng L
J Control Release; 2016 Dec; 243():78-85. PubMed ID: 27717742
[TBL] [Abstract][Full Text] [Related]
4. Controlled release of triamcinolone from an episcleral micro film delivery system for open-globe eye injuries and proliferative vitreoretinopathy.
Wu S; Bian C; Li X; Chen M; Yang J; Jin Y; Shen Y; Cheng L
J Control Release; 2021 May; 333():76-90. PubMed ID: 33771623
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
Chen M; Li X; Liu J; Han Y; Cheng L
J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
[TBL] [Abstract][Full Text] [Related]
6. RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.
Kadam RS; Tyagi P; Edelhauser HF; Kompella UB
Int J Pharm; 2012 Sep; 434(1-2):140-7. PubMed ID: 22633904
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes.
Lee SJ; Kim ES; Geroski DH; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4506-14. PubMed ID: 18503001
[TBL] [Abstract][Full Text] [Related]
8. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
[TBL] [Abstract][Full Text] [Related]
9. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide.
Kim YM; Lim JO; Kim HK; Kim SY; Shin JP
Eur J Pharm Biopharm; 2008 Sep; 70(1):179-86. PubMed ID: 18667297
[TBL] [Abstract][Full Text] [Related]
10. Polymeric micelles for the ocular delivery of triamcinolone acetonide: preparation and
Safwat MA; Mansour HF; Hussein AK; Abdelwahab S; Soliman GM
Drug Deliv; 2020 Dec; 27(1):1115-1124. PubMed ID: 32720545
[TBL] [Abstract][Full Text] [Related]
11. Controlled non-invasive iontophoretic delivery of triamcinolone acetonide amino acid ester prodrugs into the posterior segment of the eye.
Santer V; Chen Y; Kalia YN
Eur J Pharm Biopharm; 2018 Nov; 132():157-167. PubMed ID: 30266666
[TBL] [Abstract][Full Text] [Related]
12. The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide.
Du W; Sun S; Xu Y; Li J; Zhao C; Lan B; Chen H; Cheng L
J Ocul Pharmacol Ther; 2013 Sep; 29(7):633-8. PubMed ID: 23597073
[TBL] [Abstract][Full Text] [Related]
13. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies.
Araújo J; Garcia ML; Mallandrich M; Souto EB; Calpena AC
Nanomedicine; 2012 Aug; 8(6):1034-41. PubMed ID: 22115598
[TBL] [Abstract][Full Text] [Related]
14. Microneedle scleral patch for minimally invasive delivery of triamcinolone to the posterior segment of eye.
Roy G; Garg P; Venuganti VVK
Int J Pharm; 2022 Jan; 612():121305. PubMed ID: 34800618
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes.
Park HJ; Lee JE; Kim SI; Pak KY; Oum BS; Lee JS; Jung JH; Lee JE
Retina; 2014 Apr; 34(4):801-6. PubMed ID: 24077088
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked randomised controlled trial.
Banerjee PJ; Cornelius VR; Phillips R; Lo JW; Bunce C; Kelly J; Murphy C; Edwards RT; Robertson EL; Charteris DG
Trials; 2016 Jul; 17(1):339. PubMed ID: 27449500
[TBL] [Abstract][Full Text] [Related]
17. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes.
Oliveira RC; Messias A; Siqueira RC; Bonini-Filho MA; Haddad A; Damico FM; Maia-Filho A; Crispim PT; Saliba JB; Ribeiro JA; Scott IU; Cunha AS; Jorge R
Curr Eye Res; 2012 Jan; 37(1):55-61. PubMed ID: 22029458
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
19. Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery.
Altamirano-Vallejo JC; Navarro-Partida J; Gonzalez-De la Rosa A; Hsiao JH; Olguín-Gutierrez JS; Gonzalez-Villegas AC; Keller BC; Bouzo-Lopez L; Santos A
J Ocul Pharmacol Ther; 2018 Jun; 34(5):416-425. PubMed ID: 29584529
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration.
Zarei-Ghanavati S; Malaekeh-Nikouei B; Pourmazar R; Seyedi S
J Ocul Pharmacol Ther; 2012 Oct; 28(5):502-6. PubMed ID: 22537291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
